Navigation Links
Molecular insight begins Trofex Ph. 1 trial for detection of metastatic prostate cancer
Date:6/12/2008

Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today that it has initiated a Phase 1 clinical trial for its Trofex molecular imaging program for the detection and staging of metastatic prostate cancer. The trial is designed to investigate two small molecule radiopharmaceutical candidates that target prostate-specific membrane antigen (PSMA), MIP-1072 and MIP-1095, in order to select a lead candidate for further development and commercialization. Molecular Insight is conducting the study under an exploratory Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA).

"Trofex expands our oncology portfolio into the arena of molecular imaging radiopharmaceuticals for the detection, monitoring and staging of disease such as prostate cancer, providing an important strategic complement to our portfolio of molecular radiotherapeutics for cancer," said David S. Barlow, Chairman and CEO of Molecular Insight. "Trofex is now our fourth clinical-stage program, joining Zemiva, Azedra and Onalta. Both candidate compounds in this Trofex clinical study were discovered in-house by applying our expertise in molecular targeting, drug design and radiochemistry towards the detection and monitoring of prostate cancer."

MIP-1072 and MIP-1095 are radiolabeled small molecules developed by Molecular Insight that target PSMA, a protein that is highly expressed by prostate cancer cells. PSMA is well established as a molecular target for prostate cancer and coupling it with an imaging radionuclide enables a rapid, non-invasive way to detect the location of metastatic cancer.

"Prostate cancer is the second leading cause of cancer death in men in the United States, and new methods to detect, stage and monitor disease progression are urgently needed for more effective patient management of this disease," said Dr. R. Edward Coleman, M.D., Vice-Chair, Department of Radiology, Professor of Radiology and Director of Nuclear Medicine at Duke University Medical Center. "A targeted radiopharmaceutical capable of rapidly and accurately detecting the location of metastatic prostate cancer throughout the body, including the bone, would be a significant advance in patient care."

"In preclinical studies, both MIP-1072 and MIP-1095 have demonstrated promising attributes, such as high affinity for PSMA, significant uptake into tumor cells and favorable clearance from normal tissues," said John W. Babich, Ph.D., President and CSO of Molecular Insight. "The exploratory IND process accelerated our entry into the clinic to evaluate which compound is the more promising for further development. We plan to complete this study in the second half of 2008 and then, once initial safety and imaging efficacy criteria are met, advance the selected lead candidate into expanded Phase 2 clinical development." Dr. Babich noted that preclinical data in support of MIP-1072 and MIP-1095 were presented in October 2007 at the AACR-NCI-EORTC meeting on "Molecular Targets and Cancer Therapeutics."

The trial, which will involve up to 12 patients, is a single-blind, randomized cross-over study. Patients will receive a single dose of MIP-1072 or MIP-1095, followed by a single dose of the alternate candidate compound 14 days later. The study is being conducted at Duke University Medical Center, New York Presbyterian Hospital-Cornell Medical Center and Johns Hopkins Hospital.

The primary objective of the trial is to evaluate the pharmacokinetics and organ radiation dosimetry of the two compounds in patients diagnosed with prostate cancer who have evidence of recurrent metastatic disease. Secondary objectives include assessments of excretion, metabolism, safety and optimization of tumor imaging parameters.


'/>"/>

Contact: Priscilla Harlan
priscilla.harlan@molecularinsight.com
617-492-5554
Edelman Public Relations
Source:Eurekalert

Related medicine news :

1. A new molecular zip code, and a new drug target for Huntingtons disease
2. New knock-out gene model provides molecular clues to breast cancer
3. Molecular probe paints cancer cells in living animals, Stanford researchers find
4. Story ideas from molecular & cellular proteomics
5. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
6. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
7. Molecular fingerprint of breast-cancer drug resistance can predict response to treatment
8. Molecular profiling can accurately predict survival in colon cancer patients
9. Xceed Molecular Names Fran Tuttle to Its Board of Trustees
10. Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative
11. Xceed Molecular Launches Ziplex(R) Automated Gene-Expression System at the Association for Molecular Pathology, Booth 84/85
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... January 20, 2017 , ... A new partnership between Goodwill® and ... longer use or need, from clothes to couches to dressers and bicycles. Roadie — ... them to the nearest Goodwill donation center through February 28th. , “January is ...
(Date:1/20/2017)... , ... January 20, 2017 , ... Doctor C LLC, ... attended the January ECRM trade show to continue the marketing and distribution of its ... supplement, known for providing 400 percent better absorption than traditional vitamin C supplements. At ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... enhance people’s everyday lives, recently attended the January ECRM Trade Show in Hilton ... is known for its large range of supplements that keep the body functioning ...
(Date:1/20/2017)... ... January 20, 2017 , ... "TransFlare 4K Mystique comes ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light leak transitions have a ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a heartwarming ... set out for each of his children. “The Angel” is the creation of published ... in New York City, and impassioned writer. , When asked of her new book, ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... 2017  Faruqi & Faruqi, LLP, a leading national securities ... "Company") (NASDAQ: KMPH ) of the federal securities ... and directors and underwriters of the Company,s April 16, 2015 ... lead plaintiff. The lawsuit has been filed in ... Johnson County on behalf of all those ...
(Date:1/20/2017)... Research and Markets has announced the addition of ... OTC Amplifiers, Diagnostic Instruments), Sales Volume, Company Analysis and Forecast ... ... Sales Volume, Company Analysis and Forecast to 2022 provides a ... The growing prevalence of hearing impairment coupled with an ...
(Date:1/20/2017)... 20, 2017 Stock-Callers.com today evaluates the ... SGYP ), Novo Nordisk A/S (NYSE: NVO ), ... Therapeutics Holdings Inc. (NASDAQ: PTX ). These stocks ... 19 th , 2017, finishing near its session lows. As ... over 0.7%, while shares of health care companies in the ...
Breaking Medicine Technology: